Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREATE: Adjuvant Intensified Therapy for TNBC with Residual Disease
NCT07869628Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2026
- Primary completion
- Aug 2029
01
Overview
Phase 3, randomised trial in triple-negative breast cancer (TNBC) (3 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Disease-Free Survival at 60 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07869628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869628.